

# Sterile injectable development and manufacturing

Save time, cut costs, and seamlessly advance your product with our network of sites and experts in aseptic processing. With Curia, you have a customized experience with a well-versed, dedicated program manager and team of subject matter experts from development through commercialization. Curia works with complex APIs, including generics, potent and cytotoxic compounds, highly viscous formulations and controlled substances, from clinical to commercial scale, at four advanced facilities around the world.



## **Development platform**

Modality agnostic, first principle formulation development is designed around a target product profile. Curia experts support the development of solutions, suspensions, emulsions, lipid nanoparticles and lyophilized dosage forms for both small molecule and biologic products.


350+
Formulations Developed

650+
Phase 1
Batches Released

Phase 2 / 3
Batches Released

Products

## **Comprehensive Sterile Drug Product Capabilities**



### **Pre-Formulation Research**

Characterization studies include stress studies, stability-indicating analytical method development and other physiochemical characterizations to enhance our understanding of the molecule and tailor the development approach to your unique product.

## **Formulation Development**

Identify the quality attributes that impact performance and safety, analyze manufacturability and assess stability in primary packaging for liquid and lyophilized formulations.

## **Biologics Excellence**

Camarillo, CA, specializes in analytical, high concentration formulation, and process development through GMP clinical manufacturing of a variety of complex molecule types including mAbs, proteins, peptides, LNPs, oligonucleotides and plasmid DNA. Glasgow, UK also supports highly potent and cytotoxic conjugated molecules such as ADCs.

### **Highly Viscous Products**

Curia's sites in Burlington, MA (located just outside of Boston) and Albuquerque, NM can aseptically formulate and fill products with viscosities up to 10,000+ cP.

### **Controlled Substances**

- Schedule III-V in Albuquerque, NM
- Schedule II-V in Burlington, MA
- Schedule I-V in Glasgow, UK

### **Cytotoxic / Highly Potent**

Containment for formulation and filling:

- Up to OEB4 in Albuquerque, NM
- Up to OEB5 in Glasgow, UK